<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23434908</article-id><article-id pub-id-type="pmc">3635211</article-id><article-id pub-id-type="doi">10.3390/nu5020543</article-id><article-id pub-id-type="publisher-id">nutrients-05-00543</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Effects of Lutein and Docosahexaenoic Acid Supplementation on Macular Pigment Optical Density in a Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>García-Layana</surname><given-names>Alfredo</given-names></name><xref rid="c1-nutrients-05-00543" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Recalde</surname><given-names>Sergio</given-names></name></contrib><contrib contrib-type="author"><name><surname>Alamán</surname><given-names>Angel Salinas</given-names></name></contrib><contrib contrib-type="author"><name><surname>Robredo</surname><given-names>Patricia Fernández</given-names></name></contrib></contrib-group><aff id="af1-nutrients-05-00543">Ophthalmology Department, Clinica Universidad de Navarra, C/ Pio XII 36, 31080, Pamplona, Spain; E-Mails: <email>srecalde@unav.es</email> (S.R.); <email>asalinas@unav.es</email> (A.S.A.); <email>pfrobredo@unav.es</email> (P.F.R.) </aff><author-notes><corresp id="c1-nutrients-05-00543"><label>*</label> Author to whom correspondence should be addressed; E-Mail: <email>aglayana@unav.es</email>; Tel.: +34-948-296-331; Fax: +34-948-296-500.</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>2</month><year>2013</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2013</year></pub-date><volume>5</volume><issue>2</issue><fpage>543</fpage><lpage>551</lpage><history><date date-type="received"><day>24</day><month>12</month><year>2012</year></date><date date-type="rev-recd"><day>30</day><month>1</month><year>2013</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p><offsets xml_i="3085" xml_f="3378" txt_i="11" txt_f="304">We studied the macular pigment ocular density (MPOD) in patients with early age macular degeneration (AMD) before and 1 year after nutritional supplementation with lutein and docosahexaenoic acid (DHA). Forty-four patients with AMD were randomly divided into two groups that received placebo (</offsets><italic><offsets xml_i="3386" xml_f="3387" txt_i="304" txt_f="305">n</offsets></italic><offsets xml_i="3396" xml_f="3432" txt_i="305" txt_f="341"> = 21) or a nutritional supplement (</offsets><italic><offsets xml_i="3440" xml_f="3441" txt_i="341" txt_f="342">n</offsets></italic><offsets xml_i="3450" xml_f="3877" txt_i="342" txt_f="769"> = 23, 12 mg of lutein and 280 mg of DHA daily). Heterochromatic flicker photometry was used to determine the MPOD. At baseline, the MPOD in AMD patients with placebo was 0.286 ± 0.017 meanwhile in AMD patients with supplementation it was 0.291 ± 0.016. One year later, the mean MPOD had increased by 0.059 in the placebo group and by 0.162 in patients receiving lutein and DHA. This difference between groups was significant (</offsets><italic><offsets xml_i="3885" xml_f="3886" txt_i="769" txt_f="770">p</offsets></italic><offsets xml_i="3895" xml_f="4037" txt_i="770" txt_f="909"> &lt; 0.05). Lutein and DHA supplementation is effective in increasing the MPOD and may aid in prevention of age related macular degeneration.</offsets></p></abstract><kwd-group><kwd>lutein</kwd><kwd>docosahexaenoic acid</kwd><kwd>age-related macular degeneration</kwd><kwd>macular pigment density</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="4241" xml_f="4256" txt_i="917" txt_f="932">1. Introduction</offsets></title><p><offsets xml_i="4267" xml_f="4472" txt_i="933" txt_f="1138">Understanding the pathogenesis of age-related macular degeneration (AMD), the most common cause of visual disability in elderly patients in developed countries, is advancing rapidly, but is still unclear [</offsets><xref ref-type="bibr" rid="B1-nutrients-05-00543"><offsets xml_i="4522" xml_f="4523" txt_i="1138" txt_f="1139">1</offsets></xref><offsets xml_i="4530" xml_f="4531" txt_i="1139" txt_f="1140">,</offsets><xref ref-type="bibr" rid="B2-nutrients-05-00543"><offsets xml_i="4581" xml_f="4582" txt_i="1140" txt_f="1141">2</offsets></xref><offsets xml_i="4589" xml_f="4820" txt_i="1141" txt_f="1372">]. Epidemiologic reports have suggested that diets rich in vitamins C and E, zinc, lutein, zeaxanthin, and docosahexaenoic acid (DHA) are associated with the greatest reduction in the risk of development of early and advanced AMD [</offsets><xref ref-type="bibr" rid="B3-nutrients-05-00543"><offsets xml_i="4870" xml_f="4871" txt_i="1372" txt_f="1373">3</offsets></xref><offsets xml_i="4878" xml_f="4879" txt_i="1373" txt_f="1374">,</offsets><xref ref-type="bibr" rid="B4-nutrients-05-00543"><offsets xml_i="4929" xml_f="4930" txt_i="1374" txt_f="1375">4</offsets></xref><offsets xml_i="4937" xml_f="5059" txt_i="1375" txt_f="1497">]. Higher dietary intake of lutein and zeaxanthin was associated independently with a decreased likelihood of having AMD [</offsets><xref ref-type="bibr" rid="B5-nutrients-05-00543"><offsets xml_i="5109" xml_f="5110" txt_i="1497" txt_f="1498">5</offsets></xref><offsets xml_i="5117" xml_f="5274" txt_i="1498" txt_f="1655">] and dietary omega-3 long-chain polyunsaturated fatty acid intake is associated with a decreased risk of progression from bilateral drusen to advanced AMD [</offsets><xref ref-type="bibr" rid="B6-nutrients-05-00543"><offsets xml_i="5324" xml_f="5325" txt_i="1655" txt_f="1656">6</offsets></xref><offsets xml_i="5332" xml_f="5620" txt_i="1656" txt_f="1944">]. Lutein, zeaxanthin and meso-zeaxanthin are xanthophylls (carotenoids that contain one or more polar functional groups) that selectively accumulate in the retina and are particularly dense in the foveal region, or macula, where they are the main components of the macular pigment (MP) [</offsets><xref ref-type="bibr" rid="B7-nutrients-05-00543"><offsets xml_i="5670" xml_f="5671" txt_i="1944" txt_f="1945">7</offsets></xref><offsets xml_i="5678" xml_f="5763" txt_i="1945" txt_f="2030">]. In addition, lutein is the precursor of meso-zeaxanthin, a major component of MP [</offsets><xref ref-type="bibr" rid="B8-nutrients-05-00543"><offsets xml_i="5813" xml_f="5814" txt_i="2030" txt_f="2031">8</offsets></xref><offsets xml_i="5821" xml_f="5868" txt_i="2031" txt_f="2078">]. They are known to function as antioxidants [</offsets><xref ref-type="bibr" rid="B9-nutrients-05-00543"><offsets xml_i="5918" xml_f="5919" txt_i="2078" txt_f="2079">9</offsets></xref><offsets xml_i="5926" xml_f="6064" txt_i="2079" txt_f="2217">] and blue-light filters and thereby may protect the macular retina and retinal pigment epithelium from light-initiated oxidative damage [</offsets><xref ref-type="bibr" rid="B10-nutrients-05-00543"><offsets xml_i="6115" xml_f="6117" txt_i="2217" txt_f="2219">10</offsets></xref><offsets xml_i="6124" xml_f="6281" txt_i="2219" txt_f="2376">]. Oxidative stress is high in the eye because of repeated exposure to light and the high rate of oxidative metabolism in the retina. In addition, the LAST [</offsets><xref ref-type="bibr" rid="B11-nutrients-05-00543"><offsets xml_i="6332" xml_f="6334" txt_i="2376" txt_f="2378">11</offsets></xref><offsets xml_i="6341" xml_f="6353" txt_i="2378" txt_f="2390">] and LUNA [</offsets><xref ref-type="bibr" rid="B12-nutrients-05-00543"><offsets xml_i="6404" xml_f="6406" txt_i="2390" txt_f="2392">12</offsets></xref><offsets xml_i="6413" xml_f="6507" txt_i="2392" txt_f="2486">] studies have evaluated the beneficial effect of lutein supplementation in patients with AMD.</offsets></p><p><offsets xml_i="6514" xml_f="6607" txt_i="2487" txt_f="2580">DHA is a fatty acid found in the retina, with a high concentration in the rod outer segment [</offsets><xref ref-type="bibr" rid="B13-nutrients-05-00543"><offsets xml_i="6658" xml_f="6660" txt_i="2580" txt_f="2582">13</offsets></xref><offsets xml_i="6667" xml_f="6668" txt_i="2582" txt_f="2583">,</offsets><xref ref-type="bibr" rid="B14-nutrients-05-00543"><offsets xml_i="6719" xml_f="6721" txt_i="2583" txt_f="2585">14</offsets></xref><offsets xml_i="6728" xml_f="6953" txt_i="2585" txt_f="2810">]. Because photoreceptor outer segments are constantly being renewed, a constant supply of DHA may be required for proper retinal function. Marginal depletion may impair retinal function and influence the development of AMD [</offsets><xref ref-type="bibr" rid="B15-nutrients-05-00543"><offsets xml_i="7004" xml_f="7006" txt_i="2810" txt_f="2812">15</offsets></xref><offsets xml_i="7013" xml_f="7137" txt_i="2812" txt_f="2936">]. Moreover, in two prospective follow-up studies it was reported that DHA intake was inversely related to the risk of AMD [</offsets><xref ref-type="bibr" rid="B3-nutrients-05-00543"><offsets xml_i="7187" xml_f="7188" txt_i="2936" txt_f="2937">3</offsets></xref><offsets xml_i="7195" xml_f="7196" txt_i="2937" txt_f="2938">,</offsets><xref ref-type="bibr" rid="B16-nutrients-05-00543"><offsets xml_i="7247" xml_f="7249" txt_i="2938" txt_f="2940">16</offsets></xref><offsets xml_i="7256" xml_f="7353" txt_i="2940" txt_f="3037">]. Of note is the observation that supplemental DHA increases HDL and HDL subfractions in serum [</offsets><xref ref-type="bibr" rid="B17-nutrients-05-00543"><offsets xml_i="7404" xml_f="7406" txt_i="3037" txt_f="3039">17</offsets></xref><offsets xml_i="7413" xml_f="7414" txt_i="3039" txt_f="3040">,</offsets><xref ref-type="bibr" rid="B18-nutrients-05-00543"><offsets xml_i="7465" xml_f="7467" txt_i="3040" txt_f="3042">18</offsets></xref><offsets xml_i="7474" xml_f="7475" txt_i="3042" txt_f="3043">,</offsets><xref ref-type="bibr" rid="B19-nutrients-05-00543"><offsets xml_i="7526" xml_f="7528" txt_i="3043" txt_f="3045">19</offsets></xref><offsets xml_i="7535" xml_f="7600" txt_i="3045" txt_f="3110">]. Given that the carotenoids transport is made by lipids (HDL) [</offsets><xref ref-type="bibr" rid="B20-nutrients-05-00543"><offsets xml_i="7651" xml_f="7653" txt_i="3110" txt_f="3112">20</offsets></xref><offsets xml_i="7660" xml_f="7661" txt_i="3112" txt_f="3113">,</offsets><xref ref-type="bibr" rid="B21-nutrients-05-00543"><offsets xml_i="7712" xml_f="7714" txt_i="3113" txt_f="3115">21</offsets></xref><offsets xml_i="7721" xml_f="8142" txt_i="3115" txt_f="3536">], DHA supplementation could increase its transport to the retina and subsequently cause a MP ocular density (MPOD) increase. Therefore, DHA may, in part, decrease risk of AMD via increased transport of lutein into the macula. MPOD has been evaluated as a predictor of the retinal response to nutritional intervention with lutein in patients with AMD with the hope of retarding visual loss, disease progression, or both [</offsets><xref ref-type="bibr" rid="B22-nutrients-05-00543"><offsets xml_i="8193" xml_f="8195" txt_i="3536" txt_f="3538">22</offsets></xref><offsets xml_i="8202" xml_f="8204" txt_i="3538" txt_f="3540">].</offsets></p><p><offsets xml_i="8211" xml_f="8489" txt_i="3541" txt_f="3819">Although the formulation in the AREDS, which prevents development of advanced AMD, was comprised of vitamins C and E, beta-carotene, and zinc, currents trends in AMD nutritional prevention also are based on the use of lutein and long-chain polyunsaturated fatty acids like DHA [</offsets><xref ref-type="bibr" rid="B23-nutrients-05-00543"><offsets xml_i="8540" xml_f="8542" txt_i="3819" txt_f="3821">23</offsets></xref><offsets xml_i="8549" xml_f="8551" txt_i="3821" txt_f="3823">].</offsets></p><p><offsets xml_i="8558" xml_f="8641" txt_i="3824" txt_f="3907">Few data have been reported on the effect of the combined supplementation in MPOD [</offsets><xref ref-type="bibr" rid="B15-nutrients-05-00543"><offsets xml_i="8692" xml_f="8694" txt_i="3907" txt_f="3909">15</offsets></xref><offsets xml_i="8701" xml_f="8712" txt_i="3909" txt_f="3920">]. Johnson </offsets><italic><offsets xml_i="8720" xml_f="8726" txt_i="3920" txt_f="3926">et al.</offsets></italic><offsets xml_i="8735" xml_f="8737" txt_i="3926" txt_f="3928"> [</offsets><xref ref-type="bibr" rid="B15-nutrients-05-00543"><offsets xml_i="8788" xml_f="8790" txt_i="3928" txt_f="3930">15</offsets></xref><offsets xml_i="8797" xml_f="9094" txt_i="3930" txt_f="4227">] reported that although lutein supplementation increases MPOD in nonsmoking elderly women without AMD, when lutein and DHA were administered together, the increase in MPOD was not significant. This study investigates the influence of lutein and DHA supplementation on MPOD and vision performance.</offsets></p></sec><sec><title><offsets xml_i="9116" xml_f="9139" txt_i="4229" txt_f="4252">2. Experimental Section</offsets></title><sec><title><offsets xml_i="9159" xml_f="9198" txt_i="4253" txt_f="4292">2.1. Sample Size and Inclusion Criteria</offsets></title><p><offsets xml_i="9209" xml_f="10312" txt_i="4293" txt_f="5396">For reasons aforementioned, we conducted a small prospective study to determine the basal MPOD in 44 patients with early AMD (stage II-III AREDS classification corresponding to small/intermediate drusen and large drusen with/without pigment changes). All subjects underwent a screening examination that included a medical history and a physical examination. Volunteers with any history of lactose intolerance, liver, kidney, or pancreatic disease, anemia, insulin-dependent diabetes, hyperlipoproteinemia or alcoholism were excluded from the study. Other exclusion criteria included current use of antihistamine drugs, steroids or nonsteroidal anti-inflammatory drugs and use of any nutrient supplement for previous 2 months or carotenoid supplements for the previous 6 months. The present project has been performed following the Declaration of Helsinki, was approved by the Ethics Committee of the Clinica Universidad de Navarra and all participants received and signed an informed consent for the study. Randomization was done by coin toss by the same ophthalmologist who enrolled them in the study. </offsets></p></sec><sec><title><offsets xml_i="10334" xml_f="10366" txt_i="5398" txt_f="5430">2.2. Nutritional Supplementation</offsets></title><p><offsets xml_i="10377" xml_f="10525" txt_i="5431" txt_f="5579">The patients with AMD were distributed randomly in two groups; one group (placebo group) were asked to take two placebo tablets daily for one year (</offsets><italic><offsets xml_i="10533" xml_f="10534" txt_i="5579" txt_f="5580">n</offsets></italic><offsets xml_i="10543" xml_f="10676" txt_i="5580" txt_f="5713"> = 21), and the other group (intervention group) were asked to take two tablets daily of a supplemental complex with lutein and DHA (</offsets><italic><offsets xml_i="10684" xml_f="10685" txt_i="5713" txt_f="5714">n</offsets></italic><offsets xml_i="10694" xml_f="11198" txt_i="5714" txt_f="6218"> = 23). The two intervention tablets contained a total daily dosage of 12 mg of lutein, 0.6 mg of zeaxanthin, and 280 mg of DHA. The placebo (containing sugar) and intervention tablets presented with the same look, smell, taste, packaging, and were manufactured by the same laboratory (Laboratorios Thea, Barcelona, Spain). Patients as well as ophthalmologists were blinded as to which group were taking the placebo tablets and which group were taking the intervention tablets until the end of the study.</offsets></p></sec><sec><title><offsets xml_i="11220" xml_f="11274" txt_i="6220" txt_f="6274">2.3. Macular Pigment Ocular Density (MPOD) Measurement</offsets></title><p><offsets xml_i="11285" xml_f="11328" txt_i="6275" txt_f="6318">The instrument used was the Eye Maculometer</offsets><sup><offsets xml_i="11333" xml_f="11334" txt_i="6318" txt_f="6319">®</offsets></sup><offsets xml_i="11340" xml_f="11361" txt_i="6319" txt_f="6340"> (modified version: [</offsets><xref ref-type="bibr" rid="B24-nutrients-05-00543"><offsets xml_i="11412" xml_f="11414" txt_i="6340" txt_f="6342">24</offsets></xref><offsets xml_i="11421" xml_f="11767" txt_i="6342" txt_f="6688">], School of Biosciences, University of Westminster, London, UK) to provide central fixation for both the foveal and parafoveal condition. This device is based on Heterochromatic Flicker Photometry (HFP) and uses Light Emitting Diodes (LED) as the near monochromatic light source, similarly to other published studies for the assessment of MPOD [</offsets><xref ref-type="bibr" rid="B22-nutrients-05-00543"><offsets xml_i="11818" xml_f="11820" txt_i="6688" txt_f="6690">22</offsets></xref><offsets xml_i="11827" xml_f="11828" txt_i="6690" txt_f="6691">,</offsets><xref ref-type="bibr" rid="B24-nutrients-05-00543"><offsets xml_i="11879" xml_f="11881" txt_i="6691" txt_f="6693">24</offsets></xref><offsets xml_i="11888" xml_f="11889" txt_i="6693" txt_f="6694">,</offsets><xref ref-type="bibr" rid="B25-nutrients-05-00543"><offsets xml_i="11940" xml_f="11942" txt_i="6694" txt_f="6696">25</offsets></xref><offsets xml_i="11949" xml_f="11950" txt_i="6696" txt_f="6697">,</offsets><xref ref-type="bibr" rid="B26-nutrients-05-00543"><offsets xml_i="12001" xml_f="12003" txt_i="6697" txt_f="6699">26</offsets></xref><offsets xml_i="12010" xml_f="12011" txt_i="6699" txt_f="6700">,</offsets><xref ref-type="bibr" rid="B27-nutrients-05-00543"><offsets xml_i="12062" xml_f="12064" txt_i="6700" txt_f="6702">27</offsets></xref><offsets xml_i="12071" xml_f="12093" txt_i="6702" txt_f="6724">]. The Eye Maculometer</offsets><sup><offsets xml_i="12098" xml_f="12099" txt_i="6724" txt_f="6725">®</offsets></sup><offsets xml_i="12105" xml_f="12532" txt_i="6725" txt_f="7152"> described in 1998 had only one test field and required eccentric fixation for the parafoveal measurement. This field was imaged on the fovea by direct fixation by the subject or on a patch of retina 5 degrees from the fovea by getting the subject to fixate on a small red light placed to one side of the single test field. Many subjects found this eccentric fixation was not easy to maintain. Consequently, the Eye Maculometer</offsets><sup><offsets xml_i="12537" xml_f="12538" txt_i="7152" txt_f="7153">®</offsets></sup><offsets xml_i="12544" xml_f="12680" txt_i="7153" txt_f="7289"> was modified to provide central fixation for both the foveal and parafoveal condition. This improved device was the used in our study [</offsets><xref ref-type="bibr" rid="B24-nutrients-05-00543"><offsets xml_i="12731" xml_f="12733" txt_i="7289" txt_f="7291">24</offsets></xref><offsets xml_i="12740" xml_f="12743" txt_i="7291" txt_f="7294">]. </offsets></p></sec><sec><title><offsets xml_i="12765" xml_f="12787" txt_i="7296" txt_f="7318">2.4. Visual Parameters</offsets></title><p><offsets xml_i="12798" xml_f="13190" txt_i="7319" txt_f="7711">Visual function was tested before and after supplementation by measuring the best-corrected visual acuity with the ETDRS chart (Vectorvision, Greenville, Ohio, USA), and by contrast sensitivity with Pelli-Robson charts (Clement Clarke International, Edinburgh Way, Harlow, Essex, UK). Macular thickness was measured by Stratus optical coherence tomography (Carl Zeiss Meditec, Jena, Germany).</offsets></p></sec><sec><title><offsets xml_i="13212" xml_f="13237" txt_i="7713" txt_f="7738">2.5. Statistical Analysis</offsets></title><p><offsets xml_i="13248" xml_f="13314" txt_i="7739" txt_f="7805">Values are reported as the mean ± standard error of the mean (SEM)</offsets><italic><offsets xml_i="13322" xml_f="13323" txt_i="7805" txt_f="7806">.</offsets></italic><offsets xml_i="13332" xml_f="13572" txt_i="7806" txt_f="8046"> Statistical significance was evaluated by T student or U Mann-Whitney tests to analyze the differences between the placebo group and the nutritional supplementation group. Statistical significance was accepted at the 95% confidence level (</offsets><italic><offsets xml_i="13580" xml_f="13581" txt_i="8046" txt_f="8047">p</offsets></italic><offsets xml_i="13590" xml_f="13708" txt_i="8047" txt_f="8162"> &lt; 0.05) and analysis was performed by using the computer program SPSS (version 15.0, SPSS Inc., Chicago, IL, USA).</offsets></p></sec></sec><sec><title><offsets xml_i="13736" xml_f="13746" txt_i="8165" txt_f="8175">3. Results</offsets></title><sec><title><offsets xml_i="13766" xml_f="13798" txt_i="8176" txt_f="8208">3.1. Participant Characteristics</offsets></title><p><offsets xml_i="13809" xml_f="14209" txt_i="8209" txt_f="8609">Of 69 participants screened for this study, 44 were AMD patients that were assigned randomly to receive treatment or placebo. Of the 44 participants, 26 (59.0%) were women and 18 (41.0%) were men. Mean age ± Standard Error of Mean (S.E.M.) was 67.8 ± 9.2 years for AMD patients with placebo and 69.2 ± 7.8 years for AMD patients with supplementation. Mean body mass index ± S.E.M. was 24.8 ± 1.4 kg/m</offsets><sup><offsets xml_i="14214" xml_f="14215" txt_i="8609" txt_f="8610">2</offsets></sup><offsets xml_i="14221" xml_f="14259" txt_i="8610" txt_f="8648"> for placebo group and 25.2 ± 1.5 kg/m</offsets><sup><offsets xml_i="14264" xml_f="14265" txt_i="8648" txt_f="8649">2</offsets></sup><offsets xml_i="14271" xml_f="14398" txt_i="8649" txt_f="8776"> for supplementation group. There were not statistical differences between both groups in any of these demographic parameters (</offsets><xref ref-type="table" rid="nutrients-05-00543-t001"><offsets xml_i="14451" xml_f="14458" txt_i="8776" txt_f="8783">Table 1</offsets></xref><offsets xml_i="14465" xml_f="14467" txt_i="8783" txt_f="8785">).</offsets></p><table-wrap id="nutrients-05-00543-t001" position="float"><object-id pub-id-type="pii"><offsets xml_i="14558" xml_f="14589" txt_i="8786" txt_f="8817">nutrients-05-00543-t001_Table 1</offsets></object-id><label><offsets xml_i="14608" xml_f="14615" txt_i="8817" txt_f="8824">Table 1</offsets></label><caption><p><offsets xml_i="14635" xml_f="14821" txt_i="8824" txt_f="9010">General Parameters and basal macular pigment ocular density (MPOD) in age macular degeneration (AMD) patients with placebo and supplementation with lutein and docosahexaenoic acid (DHA).</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="14942" xml_f="14943" txt_i="9011" txt_f="9012">
</offsets></th><th align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15007" xml_f="15022" txt_i="9012" txt_f="9027">Placebo group (</offsets><italic><offsets xml_i="15030" xml_f="15031" txt_i="9027" txt_f="9028">n</offsets></italic><offsets xml_i="15040" xml_f="15046" txt_i="9028" txt_f="9034"> = 21)</offsets></th><th align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15110" xml_f="15130" txt_i="9034" txt_f="9054">Intervention group (</offsets><italic><offsets xml_i="15138" xml_f="15139" txt_i="9054" txt_f="9055">n</offsets></italic><offsets xml_i="15148" xml_f="15154" txt_i="9055" txt_f="9061"> = 23)</offsets></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15242" xml_f="15251" txt_i="9061" txt_f="9070">Men/women</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15315" xml_f="15319" txt_i="9071" txt_f="9075">8/13</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15383" xml_f="15388" txt_i="9076" txt_f="9081">10/13</offsets></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15461" xml_f="15472" txt_i="9082" txt_f="9093">Age (years)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15536" xml_f="15546" txt_i="9094" txt_f="9104">67.8 (9.2)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15610" xml_f="15620" txt_i="9105" txt_f="9115">69.2 (7.8)</offsets></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15693" xml_f="15702" txt_i="9116" txt_f="9125">BMI (kg/m</offsets><sup><offsets xml_i="15707" xml_f="15708" txt_i="9125" txt_f="9126">2</offsets></sup><offsets xml_i="15714" xml_f="15715" txt_i="9126" txt_f="9127">)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15779" xml_f="15789" txt_i="9128" txt_f="9138">24.8 (1.4)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15853" xml_f="15863" txt_i="9139" txt_f="9149">25.2 (1.5)</offsets></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="15936" xml_f="15940" txt_i="9150" txt_f="9154">MPOD</offsets><sup><offsets xml_i="15945" xml_f="15947" txt_i="9154" txt_f="9156"> a</offsets></sup></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="16017" xml_f="16030" txt_i="9157" txt_f="9170">0.286 (0.017)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="16094" xml_f="16107" txt_i="9171" txt_f="9184">0.291 (0.016)</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="16157" xml_f="16247" txt_i="9185" txt_f="9275">BMI = body mass index. Age, BMI, and MPOD measurements are expressed as the mean ± S.E.M. </offsets><sup><offsets xml_i="16252" xml_f="16253" txt_i="9275" txt_f="9276">a</offsets></sup><offsets xml_i="16259" xml_f="16260" txt_i="9276" txt_f="9277">
</offsets><italic><offsets xml_i="16268" xml_f="16269" txt_i="9277" txt_f="9278">p</offsets></italic><offsets xml_i="16278" xml_f="16289" txt_i="9278" txt_f="9286"> &lt; 0.01.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="16347" xml_f="16390" txt_i="9288" txt_f="9331">3.2. Macular Pigment Optical Density (MPOD)</offsets></title><p><offsets xml_i="16401" xml_f="16559" txt_i="9332" txt_f="9490">The baseline MPOD in the intervention group was (0.291 ± 0.016 unit) and was not statistically different from that of the placebo group (0.286 ± 0.017 unit) (</offsets><italic><offsets xml_i="16567" xml_f="16568" txt_i="9490" txt_f="9491">p</offsets></italic><offsets xml_i="16577" xml_f="16589" txt_i="9491" txt_f="9500"> &gt; 0.05, </offsets><xref ref-type="table" rid="nutrients-05-00543-t001"><offsets xml_i="16642" xml_f="16649" txt_i="9500" txt_f="9507">Table 1</offsets></xref><offsets xml_i="16656" xml_f="16658" txt_i="9507" txt_f="9509">, </offsets><xref ref-type="fig" rid="nutrients-05-00543-f001"><offsets xml_i="16709" xml_f="16717" txt_i="9509" txt_f="9517">Figure 1</offsets></xref><offsets xml_i="16724" xml_f="16824" txt_i="9517" txt_f="9617">A). Additionally, there was no significant difference between MPOD in the AREDS categories 2 and 3 (</offsets><italic><offsets xml_i="16832" xml_f="16833" txt_i="9617" txt_f="9618">p</offsets></italic><offsets xml_i="16842" xml_f="16854" txt_i="9618" txt_f="9627"> &gt; 0.05, </offsets><xref ref-type="fig" rid="nutrients-05-00543-f001"><offsets xml_i="16905" xml_f="16913" txt_i="9627" txt_f="9635">Figure 1</offsets></xref><offsets xml_i="16920" xml_f="16923" txt_i="9635" txt_f="9638">B).</offsets></p><fig id="nutrients-05-00543-f001" position="float"><label><offsets xml_i="16985" xml_f="16993" txt_i="9639" txt_f="9647">Figure 1</offsets></label><caption><p><offsets xml_i="17013" xml_f="17014" txt_i="9647" txt_f="9648">(</offsets><bold><offsets xml_i="17020" xml_f="17021" txt_i="9648" txt_f="9649">A</offsets></bold><offsets xml_i="17028" xml_f="17104" txt_i="9649" txt_f="9725">) MPOD in AMD patients with placebo and AMD patients with supplementation. (</offsets><bold><offsets xml_i="17110" xml_f="17111" txt_i="9725" txt_f="9726">B</offsets></bold><offsets xml_i="17118" xml_f="17238" txt_i="9726" txt_f="9846">) MPOD separately for the Age Related Eye Disease study (AREDS) categories 2 and 3. Data are presented as means ±S.E.M. </offsets></p></caption><graphic xlink:href="nutrients-05-00543-g001"></graphic></fig><p><offsets xml_i="17317" xml_f="17532" txt_i="9847" txt_f="10062">When we compared the MPOD values in patients with AMD after 1 year of follow-up, we found a significant increase in the supplementation group (0.453 ± 0.028 unit) compared to the placebo group (0.345 ± 0.026 unit) (</offsets><italic><offsets xml_i="17540" xml_f="17541" txt_i="10062" txt_f="10063">p</offsets></italic><offsets xml_i="17550" xml_f="17562" txt_i="10063" txt_f="10072"> &lt; 0.01, </offsets><xref ref-type="table" rid="nutrients-05-00543-t002"><offsets xml_i="17615" xml_f="17622" txt_i="10072" txt_f="10079">Table 2</offsets></xref><offsets xml_i="17629" xml_f="17631" txt_i="10079" txt_f="10081">, </offsets><xref ref-type="fig" rid="nutrients-05-00543-f002"><offsets xml_i="17682" xml_f="17690" txt_i="10081" txt_f="10089">Figure 2</offsets></xref><offsets xml_i="17697" xml_f="17797" txt_i="10089" txt_f="10189">A). Moreover, total MPOD increased very significantly after nutritional supplementation for 1 year (</offsets><italic><offsets xml_i="17805" xml_f="17806" txt_i="10189" txt_f="10190">p</offsets></italic><offsets xml_i="17815" xml_f="17827" txt_i="10190" txt_f="10199"> &lt; 0.01; </offsets><xref ref-type="fig" rid="nutrients-05-00543-f002"><offsets xml_i="17878" xml_f="17886" txt_i="10199" txt_f="10207">Figure 2</offsets></xref><offsets xml_i="17893" xml_f="18006" txt_i="10207" txt_f="10320">B). However, the VA, contrast sensitivity, and macular thickness did not change after 1 year of supplementation (</offsets><xref ref-type="table" rid="nutrients-05-00543-t002"><offsets xml_i="18059" xml_f="18066" txt_i="10320" txt_f="10327">Table 2</offsets></xref><offsets xml_i="18073" xml_f="18278" txt_i="10327" txt_f="10532">). In addition, the increase (0.059 units) in MPOD in the group taking placebo after 1 year compared to baseline was not statistically significant. When we evaluated the non-responders to supplementation, </offsets><italic><offsets xml_i="18286" xml_f="18290" txt_i="10532" txt_f="10536">i.e.</offsets></italic><offsets xml_i="18299" xml_f="18461" txt_i="10536" txt_f="10698">, patients with less than a 5% increase in the total MPOD, four of 23 were non-responders among the patients with AMD who received nutritional supplement (17.4%).</offsets></p><table-wrap id="nutrients-05-00543-t002" position="float"><object-id pub-id-type="pii"><offsets xml_i="18552" xml_f="18583" txt_i="10699" txt_f="10730">nutrients-05-00543-t002_Table 2</offsets></object-id><label><offsets xml_i="18602" xml_f="18609" txt_i="10730" txt_f="10737">Table 2</offsets></label><caption><p><offsets xml_i="18629" xml_f="18739" txt_i="10737" txt_f="10847">Ophthalmic parameters in patients with early AMD who received placebo or supplementation with lutein and DHA. </offsets></p></caption><table frame="hsides" rules="rows"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="18858" xml_f="18868" txt_i="10848" txt_f="10858">Parameters</offsets></th><th align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="18932" xml_f="18938" txt_i="10858" txt_f="10864">Period</offsets></th><th align="center" valign="middle" rowspan="1" colspan="1"><italic><offsets xml_i="19010" xml_f="19026" txt_i="10864" txt_f="10880">Placebo Group (n</offsets></italic><offsets xml_i="19035" xml_f="19036" txt_i="10880" txt_f="10881">
</offsets><italic><offsets xml_i="19044" xml_f="19045" txt_i="10881" txt_f="10882">=</offsets></italic><offsets xml_i="19054" xml_f="19055" txt_i="10882" txt_f="10883">
</offsets><italic><offsets xml_i="19063" xml_f="19066" txt_i="10883" txt_f="10886">21)</offsets></italic></th><th align="center" valign="middle" rowspan="1" colspan="1"><italic><offsets xml_i="19147" xml_f="19168" txt_i="10886" txt_f="10907">Intervention Group (n</offsets></italic><offsets xml_i="19177" xml_f="19178" txt_i="10907" txt_f="10908">
</offsets><italic><offsets xml_i="19186" xml_f="19187" txt_i="10908" txt_f="10909">=</offsets></italic><offsets xml_i="19196" xml_f="19197" txt_i="10909" txt_f="10910">
</offsets><italic><offsets xml_i="19205" xml_f="19208" txt_i="10910" txt_f="10913">23)</offsets></italic></th><th align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="19281" xml_f="19282" txt_i="10913" txt_f="10914">
</offsets><italic><offsets xml_i="19290" xml_f="19297" txt_i="10914" txt_f="10921">P Value</offsets></italic><offsets xml_i="19306" xml_f="19307" txt_i="10921" txt_f="10922">
</offsets></th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="background:#CCCCCC" colspan="1"><offsets xml_i="19422" xml_f="19426" txt_i="10922" txt_f="10926">MPOD</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="19517" xml_f="19518" txt_i="10927" txt_f="10928">
</offsets><italic><offsets xml_i="19526" xml_f="19534" txt_i="10928" txt_f="10936">Baseline</offsets></italic><offsets xml_i="19543" xml_f="19544" txt_i="10936" txt_f="10937">
</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="19635" xml_f="19648" txt_i="10938" txt_f="10951">0.286 (0.017)</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="19739" xml_f="19752" txt_i="10952" txt_f="10965">0.291 (0.016)</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="19843" xml_f="19844" txt_i="10966" txt_f="10967">
</offsets></td></tr><tr><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="19944" xml_f="19945" txt_i="10968" txt_f="10969">
</offsets><italic><offsets xml_i="19953" xml_f="19965" txt_i="10969" txt_f="10981">1 year after</offsets></italic><offsets xml_i="19974" xml_f="19975" txt_i="10981" txt_f="10982">
</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="20066" xml_f="20079" txt_i="10983" txt_f="10996">0.345 (0.026)</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="20170" xml_f="20183" txt_i="10997" txt_f="11010">0.453 (0.028)</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><italic><offsets xml_i="20282" xml_f="20283" txt_i="11011" txt_f="11012">p</offsets></italic><offsets xml_i="20292" xml_f="20302" txt_i="11012" txt_f="11019"> &lt; 0.01</offsets></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><offsets xml_i="20375" xml_f="20390" txt_i="11020" txt_f="11035">ETDRS (letters)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="20454" xml_f="20455" txt_i="11036" txt_f="11037">
</offsets><italic><offsets xml_i="20463" xml_f="20471" txt_i="11037" txt_f="11045">Baseline</offsets></italic><offsets xml_i="20480" xml_f="20481" txt_i="11045" txt_f="11046">
</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="20545" xml_f="20555" txt_i="11047" txt_f="11057">78.3 (6.2)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="20619" xml_f="20629" txt_i="11058" txt_f="11068">76.4 (8.7)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="20693" xml_f="20694" txt_i="11069" txt_f="11070">
</offsets></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="20767" xml_f="20768" txt_i="11071" txt_f="11072">
</offsets><italic><offsets xml_i="20776" xml_f="20788" txt_i="11072" txt_f="11084">1 year after</offsets></italic><offsets xml_i="20797" xml_f="20798" txt_i="11084" txt_f="11085">
</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="20862" xml_f="20872" txt_i="11086" txt_f="11096">75.9 (5.8)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="20936" xml_f="20946" txt_i="11097" txt_f="11107">74.3 (9.2)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="21010" xml_f="21012" txt_i="11108" txt_f="11110">ns</offsets></td></tr><tr><td rowspan="2" align="center" valign="middle" style="background:#CCCCCC" colspan="1"><offsets xml_i="21112" xml_f="21148" txt_i="11111" txt_f="11147">Contrast sensitivity score (letters)</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="21239" xml_f="21240" txt_i="11148" txt_f="11149">
</offsets><italic><offsets xml_i="21248" xml_f="21256" txt_i="11149" txt_f="11157">Baseline</offsets></italic><offsets xml_i="21265" xml_f="21266" txt_i="11157" txt_f="11158">
</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="21357" xml_f="21363" txt_i="11159" txt_f="11165">26 (5)</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="21454" xml_f="21459" txt_i="11166" txt_f="11171">25(5)</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="21550" xml_f="21551" txt_i="11172" txt_f="11173">
</offsets></td></tr><tr><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="21651" xml_f="21652" txt_i="11174" txt_f="11175">
</offsets><italic><offsets xml_i="21660" xml_f="21672" txt_i="11175" txt_f="11187">1 year after</offsets></italic><offsets xml_i="21681" xml_f="21682" txt_i="11187" txt_f="11188">
</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="21773" xml_f="21779" txt_i="11189" txt_f="11195">26 (6)</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="21870" xml_f="21876" txt_i="11196" txt_f="11202">26 (5)</offsets></td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1"><offsets xml_i="21967" xml_f="21969" txt_i="11203" txt_f="11205">ns</offsets></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><offsets xml_i="22042" xml_f="22068" txt_i="11206" txt_f="11232">OCT macular thickness (μm)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="22132" xml_f="22133" txt_i="11233" txt_f="11234">
</offsets><italic><offsets xml_i="22141" xml_f="22149" txt_i="11234" txt_f="11242">Baseline</offsets></italic><offsets xml_i="22158" xml_f="22159" txt_i="11242" txt_f="11243">
</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="22223" xml_f="22233" txt_i="11244" txt_f="11254">246 (20.7)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="22297" xml_f="22307" txt_i="11255" txt_f="11265">248 (32.5)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="22371" xml_f="22372" txt_i="11266" txt_f="11267">
</offsets></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="22445" xml_f="22446" txt_i="11268" txt_f="11269">
</offsets><italic><offsets xml_i="22454" xml_f="22466" txt_i="11269" txt_f="11281">1 year after</offsets></italic><offsets xml_i="22475" xml_f="22476" txt_i="11281" txt_f="11282">
</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="22540" xml_f="22550" txt_i="11283" txt_f="11293">249 (29.8)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="22614" xml_f="22624" txt_i="11294" txt_f="11304">246 (43.2)</offsets></td><td align="center" valign="middle" rowspan="1" colspan="1"><offsets xml_i="22688" xml_f="22690" txt_i="11305" txt_f="11307">ns</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="22740" xml_f="23030" txt_i="11308" txt_f="11598">BCVA = best-corrected visual acuity; OCT = optical coherence tomography. All values are expressed as the mean (± S.E.M.). The Best Corrected Visual Acuity tested with the Early Treatment Diabetic Retinopathy Study charts and contrast sensitivity are expressed in number of letters (ETDRS). </offsets><italic><offsets xml_i="23038" xml_f="23039" txt_i="11598" txt_f="11599">p</offsets></italic><offsets xml_i="23048" xml_f="23059" txt_i="11599" txt_f="11607"> &lt; 0.01.</offsets></p></fn></table-wrap-foot></table-wrap><fig id="nutrients-05-00543-f002" position="float"><label><offsets xml_i="23157" xml_f="23165" txt_i="11608" txt_f="11616">Figure 2</offsets></label><caption><p><offsets xml_i="23185" xml_f="23186" txt_i="11616" txt_f="11617">(</offsets><bold><offsets xml_i="23192" xml_f="23193" txt_i="11617" txt_f="11618">A</offsets></bold><offsets xml_i="23200" xml_f="23304" txt_i="11618" txt_f="11722">) MPOD in AMD placebo group and AMD supplemented group at time 0 (basal) and one year after treatment. (</offsets><bold><offsets xml_i="23310" xml_f="23311" txt_i="11722" txt_f="11723">B</offsets></bold><offsets xml_i="23318" xml_f="23441" txt_i="11723" txt_f="11846">) The MPOD change (1 year–0 month) in AMD placebo group and AMD supplemented group. Data are presented as means ±S.E.M. ** </offsets><italic><offsets xml_i="23449" xml_f="23450" txt_i="11846" txt_f="11847">p</offsets></italic><offsets xml_i="23459" xml_f="23469" txt_i="11847" txt_f="11854"> &lt;0.01.</offsets></p></caption><graphic xlink:href="nutrients-05-00543-g002"></graphic></fig></sec></sec><sec><title><offsets xml_i="23569" xml_f="23582" txt_i="11857" txt_f="11870">4. Discussion</offsets></title><p><offsets xml_i="23593" xml_f="24231" txt_i="11871" txt_f="12509">This study investigates the influence of lutein and DHA supplementation on MPOD and vision performance. We found a significant increase in the MPOD levels in patients with AMD treated for 1 year with nutritional supplementation compared with the patients with AMD who received placebo, indicating that supplemental pills with lutein and DHA can significantly improve MP and increase retinal antioxidant protection in patients with this retinal disease. These results also agree with other similar studies and reaffirmed the hypothesis that the lutein and zeaxanthin macular concentrations constitute a modifiable nutritional risk factor [</offsets><xref ref-type="bibr" rid="B28-nutrients-05-00543"><offsets xml_i="24282" xml_f="24284" txt_i="12509" txt_f="12511">28</offsets></xref><offsets xml_i="24291" xml_f="24393" txt_i="12511" txt_f="12613">]. However, visual function did not improve after supplementation, a result also reported previously [</offsets><xref ref-type="bibr" rid="B29-nutrients-05-00543"><offsets xml_i="24444" xml_f="24446" txt_i="12613" txt_f="12615">29</offsets></xref><offsets xml_i="24453" xml_f="24747" txt_i="12615" txt_f="12909">]. Of note is that the increase in MPOD in the group taking placebo was not statistically significant. Our hypothesis is that those patients suffered the “placebo effect” and their behavior on dietetics could have changed. Probably, they were more motivated and took better care of themselves. </offsets></p><p><offsets xml_i="24754" xml_f="24797" txt_i="12910" txt_f="12953">Our results differed from those of Johnson </offsets><italic><offsets xml_i="24805" xml_f="24811" txt_i="12953" txt_f="12959">et al.</offsets></italic><offsets xml_i="24820" xml_f="24822" txt_i="12959" txt_f="12961"> [</offsets><xref ref-type="bibr" rid="B15-nutrients-05-00543"><offsets xml_i="24873" xml_f="24875" txt_i="12961" txt_f="12963">15</offsets></xref><offsets xml_i="24882" xml_f="25131" txt_i="12963" txt_f="13212">] who found that the MPOD did not differ significantly when lutein and DHA were administered together. However, there are several differences between both populations that may explain that difference. Firstly, the population in the study of Johnson </offsets><italic><offsets xml_i="25139" xml_f="25145" txt_i="13212" txt_f="13218">et al.</offsets></italic><offsets xml_i="25154" xml_f="25575" txt_i="13218" txt_f="13639"> was comprised of only women, and the current study included both genders. Secondly and probably more important, the population in the study of Johnson were patients without AMD and our supplementation was given to patients with AMD, who may have a better response to that supplementation, because those individuals with the lowest MPOD values were in the greatest need of supplementation and the most likely to benefit [</offsets><xref ref-type="bibr" rid="B15-nutrients-05-00543"><offsets xml_i="25626" xml_f="25628" txt_i="13639" txt_f="13641">15</offsets></xref><offsets xml_i="25635" xml_f="25638" txt_i="13641" txt_f="13644">]. </offsets></p><p><offsets xml_i="25645" xml_f="25828" txt_i="13645" txt_f="13828">Additionally, the percentages of non-responders to lutein and DHA supplementation in our study were even lower than those observed by other authors in AMD patients (17.4% and 21.4%) [</offsets><xref ref-type="bibr" rid="B15-nutrients-05-00543"><offsets xml_i="25879" xml_f="25881" txt_i="13828" txt_f="13830">15</offsets></xref><offsets xml_i="25888" xml_f="25947" txt_i="13830" txt_f="13889">]. In contrast, several recent studies in normal subjects [</offsets><xref ref-type="bibr" rid="B25-nutrients-05-00543"><offsets xml_i="25998" xml_f="26000" txt_i="13889" txt_f="13891">25</offsets></xref><offsets xml_i="26007" xml_f="26100" txt_i="13891" txt_f="13984">] and healthy subjects with atypical spatial profile of MP (lack of a typical central peak) [</offsets><xref ref-type="bibr" rid="B27-nutrients-05-00543"><offsets xml_i="26151" xml_f="26153" txt_i="13984" txt_f="13986">27</offsets></xref><offsets xml_i="26160" xml_f="26414" txt_i="13986" txt_f="14237">] showed a low rate of non-responders (&lt;5%) because of the rapid increase in MP by the meso-zeaxanthin supplementation. They suggested that family history of AMD and smoking cigarettes may inhibit meso-zeaxanthin generation from lutein at the macula [</offsets><xref ref-type="bibr" rid="B25-nutrients-05-00543"><offsets xml_i="26465" xml_f="26467" txt_i="14237" txt_f="14239">25</offsets></xref><offsets xml_i="26474" xml_f="26475" txt_i="14239" txt_f="14240">,</offsets><xref ref-type="bibr" rid="B27-nutrients-05-00543"><offsets xml_i="26526" xml_f="26528" txt_i="14240" txt_f="14242">27</offsets></xref><offsets xml_i="26535" xml_f="26769" txt_i="14242" txt_f="14476">]. This hypothesis could explain the high rate of non-responder in our older AMD population supplemented with lutein given that it is well documented that atypical spatial profiles are more common in older subjects like AMD patients [</offsets><xref ref-type="bibr" rid="B26-nutrients-05-00543"><offsets xml_i="26820" xml_f="26822" txt_i="14476" txt_f="14478">26</offsets></xref><offsets xml_i="26829" xml_f="27134" txt_i="14478" txt_f="14783">]. Moreover, it is possible that the non-responders in supplementation studies are individuals who lack the ability to convert lutein into meso-zeaxanthin. However, recent data has shown that when meso-zeaxanthin is provided in a supplement, it has a rapid and dramatic effect on serum carotenoid levels [</offsets><xref ref-type="bibr" rid="B27-nutrients-05-00543"><offsets xml_i="27185" xml_f="27187" txt_i="14783" txt_f="14785">27</offsets></xref><offsets xml_i="27194" xml_f="27195" txt_i="14785" txt_f="14786">,</offsets><xref ref-type="bibr" rid="B30-nutrients-05-00543"><offsets xml_i="27246" xml_f="27248" txt_i="14786" txt_f="14788">30</offsets></xref><offsets xml_i="27255" xml_f="27355" txt_i="14788" txt_f="14888">]. Thus, in our non-responders meso-zeaxanthin supplementation could be more effective than lutein. </offsets></p><p><offsets xml_i="27362" xml_f="27690" txt_i="14889" txt_f="15217">Our device is based on the subjective HFP method, however several limitation need to be taken into account. For example: The inability to customise the flicker and the fact that this works in an independent mode as opposed to the yoked mode. However, we have found similar results than other authors using objective techniques [</offsets><xref ref-type="bibr" rid="B28-nutrients-05-00543"><offsets xml_i="27741" xml_f="27743" txt_i="15217" txt_f="15219">28</offsets></xref><offsets xml_i="27750" xml_f="28194" txt_i="15219" txt_f="15663">]. Moreover, another limitation was the small sample size and the use of a subjective technique such as HFP. Therefore, the results obtained herein should be interpreted with full appreciation of their sample size and the device. This fact could result in a likelihood of chance findings in either direction. Thus, it would be necessary to complete the study with more information with respect to diet, smoking, exercise, plasma lutein levels, </offsets><italic><offsets xml_i="28202" xml_f="28205" txt_i="15663" txt_f="15666">etc</offsets></italic><offsets xml_i="28214" xml_f="28215" txt_i="15666" txt_f="15667">.</offsets></p></sec><sec><title><offsets xml_i="28237" xml_f="28251" txt_i="15669" txt_f="15683">5. Conclusions</offsets></title><p><offsets xml_i="28262" xml_f="28498" txt_i="15684" txt_f="15920">In conclusion, the daily intake of a nutritional complex containing 12 mg of lutein, 0.6 mg of zeaxanthin, and 280 mg of DHA had a beneficial effect on the MPOD levels in patients with AMD. However further clinical trials like AREDS 2 [</offsets><xref ref-type="bibr" rid="B31-nutrients-05-00543"><offsets xml_i="28549" xml_f="28551" txt_i="15920" txt_f="15922">31</offsets></xref><offsets xml_i="28558" xml_f="28734" txt_i="15922" txt_f="16098">] are required to investigate the optimum dosage levels of all vitamins, micronutrients, and carotenoids that will protect the retina against degenerative diseases such as AMD.</offsets></p></sec></body><back><ack><title>Acknowledgements</title><p>Authors want to thank to all patients that collaborated in the present project. Funding: “The present work was partially funded by a Thea Laboratoires’ Grant and partially supported by RETICS (RD07/0062) from ISCIII, Ministerio de Ciencia e Innovación, Spain”.</p></ack><notes><title>Conflict of Interest</title><p>The authors declare no conflict of interest. </p></notes><ref-list><title>References</title><ref id="B1-nutrients-05-00543"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klaver</surname><given-names>C.C.</given-names></name><name><surname>Wolfs</surname><given-names>R.C.</given-names></name><name><surname>Vingerling</surname><given-names>J.R.</given-names></name><name><surname>Hofman</surname><given-names>A.</given-names></name><name><surname>de Jong</surname><given-names>P.T.</given-names></name></person-group>
<article-title>Age-specific prevalence and causes of blindness and visual impairment in an older population: The Rotterdam Study</article-title>
<source>Arch. Ophthalmol.</source>
<year>1998</year>
<volume>116</volume>
<fpage>653</fpage>
<lpage>658</lpage>
<pub-id pub-id-type="pmid">9596502</pub-id></element-citation></ref><ref id="B2-nutrients-05-00543"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klein</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Klein</surname><given-names>B.E.</given-names></name><name><surname>Moss</surname><given-names>S.E.</given-names></name><name><surname>Meuer</surname><given-names>S.M.</given-names></name></person-group>
<article-title>The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity</article-title>
<source>Invest. Ophthalmol. Vis. Sci.</source>
<year>1995</year>
<volume>36</volume>
<fpage>182</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="pmid">7822146</pub-id></element-citation></ref><ref id="B3-nutrients-05-00543"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>E.</given-names></name><name><surname>Hung</surname><given-names>S.</given-names></name><name><surname>Willett</surname><given-names>W.C.</given-names></name><name><surname>Spiegelman</surname><given-names>D.</given-names></name><name><surname>Rimm</surname><given-names>E.B.</given-names></name><name><surname>Seddon</surname><given-names>J.M.</given-names></name><name><surname>Colditz</surname><given-names>G.A.</given-names></name><name><surname>Hankinson</surname><given-names>S.E.</given-names></name></person-group>
<article-title>Prospective study of dietary fat and the risk of age-related macular degeneration</article-title>
<source>Am. J. Clin. Nutr.</source>
<year>2001</year>
<volume>73</volume>
<fpage>209</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="pmid">11157315</pub-id></element-citation></ref><ref id="B4-nutrients-05-00543"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Landrum</surname><given-names>J.T.</given-names></name><name><surname>Bone</surname><given-names>R.A.</given-names></name></person-group>
<article-title>Lutein, zeaxanthin, and the macular pigment</article-title>
<source>Arch. Biochem. Biophys.</source>
<year>2001</year>
<volume>385</volume>
<fpage>28</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1006/abbi.2000.2171</pub-id>
<pub-id pub-id-type="pmid">11361022</pub-id></element-citation></ref><ref id="B5-nutrients-05-00543"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>SanGiovanni</surname><given-names>J.P.</given-names></name><name><surname>Chew</surname><given-names>E.Y.</given-names></name><name><surname>Clemons</surname><given-names>T.E.</given-names></name><name><surname>Ferris</surname><given-names>F.L.</given-names><suffix>3rd</suffix></name><name><surname>Gensler</surname><given-names>G.</given-names></name><name><surname>Lindblad</surname><given-names>A.S.</given-names></name><name><surname>Milton</surname><given-names>R.C.</given-names></name><name><surname>Seddon</surname><given-names>J.M.</given-names></name><name><surname>Sperduto</surname><given-names>R.D.</given-names></name></person-group>
<article-title>The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22</article-title>
<source>Arch. Ophthalmol.</source>
<year>2007</year>
<volume>125</volume>
<fpage>1225</fpage>
<lpage>1232</lpage>
<pub-id pub-id-type="doi">10.1001/archopht.125.9.1225</pub-id>
<pub-id pub-id-type="pmid">17846363</pub-id></element-citation></ref><ref id="B6-nutrients-05-00543"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>SanGiovanni</surname><given-names>J.P.</given-names></name><name><surname>Chew</surname><given-names>E.Y.</given-names></name><name><surname>Agron</surname><given-names>E.</given-names></name><name><surname>Clemons</surname><given-names>T.E.</given-names></name><name><surname>Ferris</surname><given-names>F.L.</given-names><suffix>3rd</suffix></name><name><surname>Gensler</surname><given-names>G.</given-names></name><name><surname>Lindblad</surname><given-names>A.S.</given-names></name><name><surname>Milton</surname><given-names>R.C.</given-names></name><name><surname>Seddon</surname><given-names>J.M.</given-names></name><name><surname>Klein</surname><given-names>R.</given-names></name><etal></etal></person-group>
<article-title>The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23</article-title>
<source>Arch. Ophthalmol.</source>
<year>2008</year>
<volume>126</volume>
<fpage>1274</fpage>
<lpage>1279</lpage>
<pub-id pub-id-type="doi">10.1001/archopht.126.9.1274</pub-id>
<pub-id pub-id-type="pmid">18779490</pub-id></element-citation></ref><ref id="B7-nutrients-05-00543"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Snodderly</surname><given-names>D.M.</given-names></name></person-group>
<article-title>Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins</article-title>
<source>Am. J. Clin. Nutr.</source>
<year>1995</year>
<volume>62</volume>
<fpage>1448S</fpage>
<lpage>1461S</lpage>
<pub-id pub-id-type="pmid">7495246</pub-id></element-citation></ref><ref id="B8-nutrients-05-00543"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>E.J.</given-names></name><name><surname>Neuringer</surname><given-names>M.</given-names></name><name><surname>Russell</surname><given-names>R.M.</given-names></name><name><surname>Schalch</surname><given-names>W.</given-names></name><name><surname>Snodderly</surname><given-names>D.M.</given-names></name></person-group>
<article-title>Nutritional manipulation of primate retinas, III: Effects of lutein or zeaxanthin supplementation on adipose tissue and retina of xanthophyll-free monkeys</article-title>
<source>Invest. Ophthalmol. Vis. Sci.</source>
<year>2005</year>
<volume>46</volume>
<fpage>692</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1167/iovs.02-1192</pub-id>
<pub-id pub-id-type="pmid">15671301</pub-id></element-citation></ref><ref id="B9-nutrients-05-00543"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schalch</surname><given-names>W.</given-names></name></person-group>
<article-title>Carotenoids in the retina—a review of their possible role in preventing or limiting damage caused by light and oxygen</article-title>
<source>EXS</source>
<year>1992</year>
<volume>62</volume>
<fpage>280</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="pmid">1450592</pub-id></element-citation></ref><ref id="B10-nutrients-05-00543"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hammond</surname><given-names>B.R.</given-names><suffix>Jr.</suffix></name><name><surname>Wooten</surname><given-names>B.R.</given-names></name><name><surname>Snodderly</surname><given-names>D.M.</given-names></name></person-group>
<article-title>Preservation of visual sensitivity of older subjects: association with macular pigment density</article-title>
<source>Invest. Ophthalmol. Vis. Sci.</source>
<year>1998</year>
<volume>39</volume>
<fpage>397</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="pmid">9478000</pub-id></element-citation></ref><ref id="B11-nutrients-05-00543"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Richer</surname><given-names>S.</given-names></name><name><surname>Stiles</surname><given-names>W.</given-names></name><name><surname>Statkute</surname><given-names>L.</given-names></name><name><surname>Pulido</surname><given-names>J.</given-names></name><name><surname>Frankowski</surname><given-names>J.</given-names></name><name><surname>Rudy</surname><given-names>D.</given-names></name><name><surname>Pei</surname><given-names>K.</given-names></name><name><surname>Tsipursky</surname><given-names>M.</given-names></name><name><surname>Nyland</surname><given-names>J.</given-names></name></person-group>
<article-title>Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: The Veterans LAST study (Lutein Antioxidant Supplementation Trial)</article-title>
<source>Optometry</source>
<year>2004</year>
<volume>75</volume>
<fpage>216</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="doi">10.1016/S1529-1839(04)70049-4</pub-id>
<pub-id pub-id-type="pmid">15117055</pub-id></element-citation></ref><ref id="B12-nutrients-05-00543"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trieschmann</surname><given-names>M.</given-names></name><name><surname>Beatty</surname><given-names>S.</given-names></name><name><surname>Nolan</surname><given-names>J.M.</given-names></name><name><surname>Hense</surname><given-names>H.W.</given-names></name><name><surname>Heimes</surname><given-names>B.</given-names></name><name><surname>Austermann</surname><given-names>U.</given-names></name><name><surname>Fobker</surname><given-names>M.</given-names></name><name><surname>Pauleikhoff</surname><given-names>D.</given-names></name></person-group>
<article-title>Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: The LUNA study</article-title>
<source>Exp. Eye Res.</source>
<year>2007</year>
<volume>84</volume>
<fpage>718</fpage>
<lpage>728</lpage>
<pub-id pub-id-type="doi">10.1016/j.exer.2006.12.010</pub-id>
<pub-id pub-id-type="pmid">17306793</pub-id></element-citation></ref><ref id="B13-nutrients-05-00543"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bazan</surname><given-names>N.G.</given-names></name><name><surname>Reddy</surname><given-names>T.S.</given-names></name><name><surname>Bazan</surname><given-names>H.E.</given-names></name><name><surname>Birkle</surname><given-names>D.L.</given-names></name></person-group>
<article-title>Metabolism of arachidonic and docosahexaenoic acids in the retina</article-title>
<source>Prog. Lipid Res.</source>
<year>1986</year>
<volume>25</volume>
<fpage>595</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1016/0163-7827(86)90122-0</pub-id>
<pub-id pub-id-type="pmid">3122231</pub-id></element-citation></ref><ref id="B14-nutrients-05-00543"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fliesler</surname><given-names>S.J.</given-names></name><name><surname>Anderson</surname><given-names>R.E.</given-names></name></person-group>
<article-title>Chemistry and metabolism of lipids in the vertebrate retina</article-title>
<source>Prog. Lipid Res.</source>
<year>1983</year>
<volume>22</volume>
<fpage>79</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="doi">10.1016/0163-7827(83)90004-8</pub-id>
<pub-id pub-id-type="pmid">6348799</pub-id></element-citation></ref><ref id="B15-nutrients-05-00543"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>E.J.</given-names></name><name><surname>Chung</surname><given-names>H.Y.</given-names></name><name><surname>Caldarella</surname><given-names>S.M.</given-names></name><name><surname>Snodderly</surname><given-names>D.M.</given-names></name></person-group>
<article-title>The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation</article-title>
<source>Am. J. Clin. Nutr.</source>
<year>2008</year>
<volume>87</volume>
<fpage>1521</fpage>
<lpage>1529</lpage>
<pub-id pub-id-type="pmid">18469279</pub-id></element-citation></ref><ref id="B16-nutrients-05-00543"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seddon</surname><given-names>J.M.</given-names></name><name><surname>Cote</surname><given-names>J.</given-names></name><name><surname>Rosner</surname><given-names>B.</given-names></name></person-group>
<article-title>Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake</article-title>
<source>Arch. Ophthalmol.</source>
<year>2003</year>
<volume>121</volume>
<fpage>1728</fpage>
<lpage>1737</lpage>
<pub-id pub-id-type="doi">10.1001/archopht.121.12.1728</pub-id>
<pub-id pub-id-type="pmid">14662593</pub-id></element-citation></ref><ref id="B17-nutrients-05-00543"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Foulon</surname><given-names>T.</given-names></name><name><surname>Richard</surname><given-names>M.J.</given-names></name><name><surname>Payen</surname><given-names>N.</given-names></name><name><surname>Bourrain</surname><given-names>J.L.</given-names></name><name><surname>Beani</surname><given-names>J.C.</given-names></name><name><surname>Laporte</surname><given-names>F.</given-names></name><name><surname>Hadjian</surname><given-names>A.</given-names></name></person-group>
<article-title>Effects of fish oil fatty acids on plasma lipids and lipoproteins and oxidant-antioxidant imbalance in healthy subjects</article-title>
<source>Scand. J. Clin. Lab. Invest.</source>
<year>1999</year>
<volume>59</volume>
<fpage>239</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="doi">10.1080/00365519950185607</pub-id>
<pub-id pub-id-type="pmid">10463462</pub-id></element-citation></ref><ref id="B18-nutrients-05-00543"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nelson</surname><given-names>G.J.</given-names></name><name><surname>Schmidt</surname><given-names>P.C.</given-names></name><name><surname>Bartolini</surname><given-names>G.L.</given-names></name><name><surname>Kelley</surname><given-names>D.S.</given-names></name><name><surname>Kyle</surname><given-names>D.</given-names></name></person-group>
<article-title>The effect of dietary docosahexaenoic acid on plasma lipoproteins and tissue fatty acid composition in humans</article-title>
<source>Lipids</source>
<year>1997</year>
<volume>32</volume>
<fpage>1137</fpage>
<lpage>1146</lpage>
<pub-id pub-id-type="doi">10.1007/s11745-997-0146-5</pub-id>
<pub-id pub-id-type="pmid">9397398</pub-id></element-citation></ref><ref id="B19-nutrients-05-00543"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomas</surname><given-names>T.R.</given-names></name><name><surname>Smith</surname><given-names>B.K.</given-names></name><name><surname>Donahue</surname><given-names>O.M.</given-names></name><name><surname>Altena</surname><given-names>T.S.</given-names></name><name><surname>James-Kracke</surname><given-names>M.</given-names></name><name><surname>Sun</surname><given-names>G.Y.</given-names></name></person-group>
<article-title>Effects of omega-3 fatty acid supplementation and exercise on low-density lipoprotein and high-density lipoprotein subfractions</article-title>
<source>Metabolism</source>
<year>2004</year>
<volume>53</volume>
<fpage>749</fpage>
<lpage>754</lpage>
<pub-id pub-id-type="doi">10.1016/j.metabol.2003.12.019</pub-id>
<pub-id pub-id-type="pmid">15164323</pub-id></element-citation></ref><ref id="B20-nutrients-05-00543"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cardinault</surname><given-names>N.</given-names></name><name><surname>Abalain</surname><given-names>J.H.</given-names></name><name><surname>Sairafi</surname><given-names>B.</given-names></name><name><surname>Coudray</surname><given-names>C.</given-names></name><name><surname>Grolier</surname><given-names>P.</given-names></name><name><surname>Rambeau</surname><given-names>M.</given-names></name><name><surname>Carre</surname><given-names>J.L.</given-names></name><name><surname>Mazur</surname><given-names>A.</given-names></name><name><surname>Rock</surname><given-names>E.</given-names></name></person-group>
<article-title>Lycopene but not lutein nor zeaxanthin decreases in serum and lipoproteins in age-related macular degeneration patients</article-title>
<source>Clin. Chim. Acta</source>
<year>2005</year>
<volume>357</volume>
<fpage>34</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1016/j.cccn.2005.01.030</pub-id>
<pub-id pub-id-type="pmid">15963792</pub-id></element-citation></ref><ref id="B21-nutrients-05-00543"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parker</surname><given-names>R.S.</given-names></name></person-group>
<article-title>Absorption, metabolism, and transport of carotenoids</article-title>
<source>FASEB J.</source>
<year>1996</year>
<volume>10</volume>
<fpage>542</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="pmid">8621054</pub-id></element-citation></ref><ref id="B22-nutrients-05-00543"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stringham</surname><given-names>J.M.</given-names></name><name><surname>Hammond</surname><given-names>B.R.</given-names></name><name><surname>Nolan</surname><given-names>J.M.</given-names></name><name><surname>Wooten</surname><given-names>B.R.</given-names></name><name><surname>Mammen</surname><given-names>A.</given-names></name><name><surname>Smollon</surname><given-names>W.</given-names></name><name><surname>Snodderly</surname><given-names>D.M.</given-names></name></person-group>
<article-title>The utility of using customized heterochromatic flicker photometry (cHFP) to measure macular pigment in patients with age-related macular degeneration</article-title>
<source>Exp. Eye Res.</source>
<year>2008</year>
<volume>87</volume>
<fpage>445</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="doi">10.1016/j.exer.2008.08.005</pub-id>
<pub-id pub-id-type="pmid">18778703</pub-id></element-citation></ref><ref id="B23-nutrients-05-00543"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coleman</surname><given-names>H.</given-names></name><name><surname>Chew</surname><given-names>E.</given-names></name></person-group>
<article-title>Nutritional supplementation in age-related macular degeneration</article-title>
<source>Curr. Opin. Ophthalmol.</source>
<year>2007</year>
<volume>18</volume>
<fpage>220</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1097/ICU.0b013e32814a586b</pub-id>
<pub-id pub-id-type="pmid">17435429</pub-id></element-citation></ref><ref id="B24-nutrients-05-00543"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mellerio</surname><given-names>J.</given-names></name><name><surname>Ahmadi-Lari</surname><given-names>S.</given-names></name><name><surname>van Kuijk</surname><given-names>F.</given-names></name><name><surname>Pauleikhoff</surname><given-names>D.</given-names></name><name><surname>Bird</surname><given-names>A.</given-names></name><name><surname>Marshall</surname><given-names>J.</given-names></name></person-group>
<article-title>A portable instrument for measuring macular pigment with central fixation</article-title>
<source>Curr. Eye Res.</source>
<year>2002</year>
<volume>25</volume>
<fpage>37</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1076/ceyr.25.1.37.9961</pub-id>
<pub-id pub-id-type="pmid">12518242</pub-id></element-citation></ref><ref id="B25-nutrients-05-00543"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Connolly</surname><given-names>E.E.</given-names></name><name><surname>Beatty</surname><given-names>S.</given-names></name><name><surname>Loughman</surname><given-names>J.</given-names></name><name><surname>Howard</surname><given-names>A.N.</given-names></name><name><surname>Louw</surname><given-names>M.S.</given-names></name><name><surname>Nolan</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Supplementation with all three macular carotenoids: response, stability, and safety</article-title>
<source>Invest. Ophthalmol. Vis. Sci.</source>
<year>2011</year>
<volume>52</volume>
<fpage>9207</fpage>
<lpage>9217</lpage>
<pub-id pub-id-type="doi">10.1167/iovs.11-8025</pub-id>
<pub-id pub-id-type="pmid">21979997</pub-id></element-citation></ref><ref id="B26-nutrients-05-00543"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirby</surname><given-names>M.L.</given-names></name><name><surname>Beatty</surname><given-names>S.</given-names></name><name><surname>Loane</surname><given-names>E.</given-names></name><name><surname>Akkali</surname><given-names>M.C.</given-names></name><name><surname>Connolly</surname><given-names>E.E.</given-names></name><name><surname>Stack</surname><given-names>J.</given-names></name><name><surname>Nolan</surname><given-names>J.M.</given-names></name></person-group>
<article-title>A central dip in the macular pigment spatial profile is associated with age and smoking</article-title>
<source>Invest. Ophthalmol. Vis. Sci.</source>
<year>2010</year>
<volume>51</volume>
<fpage>6722</fpage>
<lpage>6728</lpage>
<pub-id pub-id-type="doi">10.1167/iovs.10-5344</pub-id>
<pub-id pub-id-type="pmid">20592234</pub-id></element-citation></ref><ref id="B27-nutrients-05-00543"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nolan</surname><given-names>J.M.</given-names></name><name><surname>Akkali</surname><given-names>M.C.</given-names></name><name><surname>Loughman</surname><given-names>J.</given-names></name><name><surname>Howard</surname><given-names>A.N.</given-names></name><name><surname>Beatty</surname><given-names>S.</given-names></name></person-group>
<article-title>Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment</article-title>
<source>Exp. Eye Res.</source>
<year>2012</year>
<volume>101</volume>
<fpage>9</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/j.exer.2012.05.006</pub-id>
<pub-id pub-id-type="pmid">22652506</pub-id></element-citation></ref><ref id="B28-nutrients-05-00543"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaya</surname><given-names>S.</given-names></name><name><surname>Weigert</surname><given-names>G.</given-names></name><name><surname>Pemp</surname><given-names>B.</given-names></name><name><surname>Sacu</surname><given-names>S.</given-names></name><name><surname>Werkmeister</surname><given-names>R.M.</given-names></name><name><surname>Dragostinoff</surname><given-names>N.</given-names></name><name><surname>Garhofer</surname><given-names>G.</given-names></name><name><surname>Schmidt-Erfurth</surname><given-names>U.</given-names></name><name><surname>Schmetterer</surname><given-names>L.</given-names></name></person-group>
<article-title>Comparison of macular pigment in patients with age-related macular degeneration and healthy control subjects—a study using spectral fundus reflectance</article-title>
<source>Acta Ophthalmol.</source>
<year>2012</year>
<volume>90</volume>
<fpage>e399</fpage>
<lpage>e403</lpage>
<pub-id pub-id-type="doi">10.1111/j.1755-3768.2012.02423.x</pub-id>
<pub-id pub-id-type="pmid">23035764</pub-id></element-citation></ref><ref id="B29-nutrients-05-00543"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>H.E.</given-names></name><name><surname>Eperjesi</surname><given-names>F.</given-names></name></person-group>
<article-title>Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: A randomized controlled trial</article-title>
<source>Eur J. Clin. Nutr.</source>
<year>2007</year>
<volume>61</volume>
<fpage>1121</fpage>
<lpage>1127</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejcn.1602626</pub-id>
<pub-id pub-id-type="pmid">17268417</pub-id></element-citation></ref><ref id="B30-nutrients-05-00543"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meagher</surname><given-names>K.A.</given-names></name><name><surname>Thurnham</surname><given-names>D.I.</given-names></name><name><surname>Beatty</surname><given-names>S.</given-names></name><name><surname>Howard</surname><given-names>A.N.</given-names></name><name><surname>Connolly</surname><given-names>E.</given-names></name><name><surname>Cummins</surname><given-names>W.</given-names></name><name><surname>Nolan</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration</article-title>
<source>Br. J. Nutr.</source>
<year>2012</year>
<volume>5</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">23211762</pub-id></element-citation></ref><ref id="B31-nutrients-05-00543"><label>31.</label><element-citation publication-type="webpage">
<article-title>Age-Related Eye Disease Study 2</article-title>
<comment>Available online:<ext-link ext-link-type="uri" xlink:href="http://www.areds2.org/">http://www.areds2.org/</ext-link></comment><date-in-citation>(accessed on 6 February 2013)</date-in-citation>
</element-citation></ref></ref-list></back></article>